Marksans Pharma arm adds Metformin Hydrochloride 500mg/ 5 ml Oral Solution to growing list of UK approved medicines

Mumbai: Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited has received marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.

Metformin is widely used as a first-line treatment for type 2 diabetes, and this approval strengthens Relonchem’s presence in the UK oral antidiabetic drug market.

This marks the third regulatory approval granted to Relonchem in the UK this month. Earlier in May, the company received marketing authorization for Sennosides 7.5 mg Tablets and Gabapentin 50 mg/ml Oral Solution.

Read also: Marksans Pharma arm Relonchem gets marketing authorization for Sennosides Tablets in UK

In March 2025, Relonchem had also received UK MHRA approval for Baclofen 10 mg Tablets, a medication used to relax specific muscles in the body, relieving spasms, cramps, and tightness associated with multiple sclerosis or spinal injuries.

Read also: Marksans Pharma arm gets marketing authorization for muscle relaxant tablets in UK

In February 2025, Relonchem was granted marketing authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell's Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets).

Read also: Marksans Pharma UK arm gets marketing nod for Ibuprofen, Paracetamol Film-coated Tablets

Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.